Nipro (8086) AI Stock Analysis

• Market Cap: ¥236.65B
• Dividend Yield: 2.07%
• Average Volume (3M): 511.40K
• Price to Earnings (P/E): 21.7
• Beta (1Y): 0.41
• Revenue Growth: 6.04%
• EPS Growth: 733.13%
• Country: JP
• Employees: 38,117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 16.15
• Shares Outstanding: 171,459,470
• 10 Day Avg. Volume: 428,610
• 30 Day Avg. Volume: 511,400
• PEG Ratio: -0.80
• Price to Book (P/B): 0.88
• Price to Sales (P/S): 0.34
• P/FCF Ratio: -27.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥1,505.30
• Price Target Upside: 0.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): 71.05
• Revenue Forecast (FY): ¥667.18B

• Rating: 62 Neutral
• Price Target: ¥1,593.00 ▲(6.02% Upside)

Nipro's overall stock score reflects a mix of financial strengths and weaknesses, with solid revenue growth but challenges in profitability and leverage. Technical indicators suggest potential short-term weakness, while a high P/E ratio indicates overvaluation. The dividend yield offers some support but may not offset valuation concerns.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and stability.

Stable Gross Margins

Stable gross margins suggest effective cost control and pricing strategies, which are crucial for maintaining profitability in competitive markets.

Strong Operating Cash Flow

Strong operating cash flow indicates the company's ability to generate cash from its core operations, ensuring liquidity and financial health.

Negative Factors

High Leverage

High leverage can increase financial risk, especially during economic downturns, potentially impacting the company's ability to invest in growth opportunities.

Negative Free Cash Flow

Negative free cash flow suggests challenges in covering capital expenditures, which could limit the company's ability to invest in new projects or technologies.

Decreased Net Profit Margin

A declining net profit margin indicates potential issues in cost management or pricing power, which could affect long-term profitability and competitiveness.

Nipro Business Overview & Revenue Model

Company Description

Nipro Corporation (8086) is a global healthcare company headquartered in Japan, specializing in the development and manufacturing of medical devices, pharmaceuticals, and biotechnology. The company operates primarily in the areas of renal care, intravenous (IV) therapy, and blood transfusion, offering a wide range of products such as dialysis equipment, infusion systems, and various medical disposables. Nipro is committed to enhancing patient outcomes through innovative technologies and high-quality healthcare solutions.

How the Company Makes Money

Nipro generates revenue through the sale of its medical devices and pharmaceutical products, catering primarily to hospitals, healthcare facilities, and distributors. Key revenue streams include the sale of dialysis equipment, IV therapy products, and blood management systems. Additionally, Nipro partners with various healthcare institutions and organizations to develop specialized products and solutions, which can lead to long-term contracts and steady income. The company also invests in research and development to introduce new technologies, ensuring a competitive edge in the healthcare market, and capitalizes on the growing demand for advanced medical treatments globally.

Nipro Financial Statement Overview

Summary

Nipro shows solid revenue growth and stable gross margins, but faces challenges in net profitability and leverage. Operating cash flow is robust, yet negative free cash flow indicates a need for improved capital management.

Income Statement

Nipro has demonstrated consistent revenue growth with a notable increase of 9.83% from 2024 to 2025. Gross profit margins have remained stable, reflecting strong cost management. However, the net profit margin has decreased due to a significant drop in net income, highlighting potential challenges in managing operating expenses or increased costs elsewhere.

Balance Sheet

The company's debt-to-equity ratio indicates high leverage, which could pose risks in economic downturns. Although total assets have increased, stockholder equity growth has not kept pace, resulting in a moderate equity ratio. Return on equity is low, suggesting challenges in generating efficient returns for shareholders.

Cash Flow

Nipro's free cash flow has shown improvement but remains negative, indicating ongoing challenges in generating surplus cash after capital expenditures. The operating cash flow to net income ratio is strong, suggesting that the company generates healthy operating cash relative to earnings, despite reduced net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	649.95B	644.59B	586.78B	545.20B	494.79B	455.56B
Gross Profit	196.66B	190.88B	171.32B	163.45B	149.27B	138.84B
EBITDA	93.53B	92.58B	84.62B	70.02B	73.54B	70.25B
Net Income	10.89B	5.11B	11.11B	4.57B	13.46B	14.21B
Balance Sheet
Total Assets	1.15T	1.18T	1.11T	1.03T	930.32B	854.40B
Cash, Cash Equivalents and Short-Term Investments	109.97B	106.67B	99.67B	89.68B	95.34B	90.27B
Total Debt	642.04B	636.87B	635.69B	605.93B	564.85B	545.28B
Total Liabilities	855.89B	864.77B	840.03B	785.23B	730.46B	680.35B
Stockholders Equity	238.94B	252.45B	232.66B	206.32B	185.24B	161.02B
Cash Flow
Free Cash Flow	0.00	-8.15B	-21.33B	-74.44B	-11.59B	14.91B
Operating Cash Flow	0.00	68.46B	72.94B	10.39B	68.21B	66.09B
Investing Cash Flow	0.00	-71.88B	-87.08B	-71.74B	-78.43B	-45.07B
Financing Cash Flow	0.00	5.38B	22.14B	43.08B	10.30B	-22.06B

Nipro Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1502.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Positive. The current price of 1502.5 is above the 20-day moving average (MA) of 1469.08, above the 50-day MA of 1488.22, and above the 200-day MA of 1385.74, indicating a neutral trend. The MACD of -12.26 indicates Positive momentum. The RSI at 46.31 is Neutral, neither overbought nor oversold. The STOCH value of 38.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8086.

Nipro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7733	72 Outperform	¥2.25T	23.54	13.13%	0.98%	0.42%	34.76%
4543	68 Neutral	¥3.42T	26.12	9.31%	1.21%	7.68%	10.08%
7747	68 Neutral	¥806.06B	53.95	10.09%	0.80%	13.53%	-7.39%
7716	66 Neutral	¥170.63B	24.96	5.66%	2.61%	5.43%	-20.67%
8086	62 Neutral	¥236.65B	21.73	4.38%	2.07%	6.04%	733.13%
6869	61 Neutral	¥912.65B	19.55	9.80%	2.03%	1.51%	-12.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nipro Corporate Events

Nipro Corporation Reports Variance in Financial Forecasts and Results

Nipro Corporation reported a discrepancy between its financial forecasts and actual results for the six months ending September 30, 2025. Despite lower-than-expected net sales due to a decline in domestic sales of medical devices and generic medicines, the company achieved higher operating and ordinary profits, attributed to decreased unrealized profit elimination and increased interest and dividend income. The profit attributable to owners exceeded forecasts due to an extraordinary gain from a real estate transaction. The company maintains its performance forecast for the fiscal year ending March 31, 2026.

Nipro Corporation Reports Financial Results for First Half of 2025

Nipro Corporation reported its consolidated financial results for the six months ending September 30, 2025, showing a slight increase in net sales by 1.7% year-on-year, reaching ¥317,382 million. The company experienced a significant rise in ordinary profit by 83.3% to ¥8,234 million, indicating improved operational efficiency. However, comprehensive income turned negative, reflecting potential challenges in certain areas of its business. The company also announced a revision in its dividend forecast, with an increase expected for the fiscal year ending March 31, 2026, which could impact shareholder returns positively.